Skip to content
  1. I3 - The International IVF Initiative
AI in PGT-A Decision-Making
AI in PGT-A Decision-Making
AI in PGT-A Decision-Making
AI in PGT-A Decision-Making

AI in PGT-A Decision-Making

Donate

At the International IVF Initiative, we are committed to providing free access to our educational sessions, webinars, and resources for professionals and individuals passionate about advancing reproductive medicine. We believe that cost should never be a barrier to knowledge and collaboration. By contributing, you’re ensuring that valuable educational resources, expert insights, and collaborative opportunities remain open to all without financial barriers. Together, we can continue to foster a global community dedicated to innovation and excellence in the field of IVF.

Your Donation
Regular price $50.00

Thank you!

 AI in PGT-A Decision-Making 

DR. MIKE LARGE

Sr. Director of Research & Development - Genomics, CooperSurgical

Dr. Mike Large
Mike was born and raised in Southeast Wisconsin. He earned is Baccalaureate of Science in Cell and Molecular Biology from the University of Wisconsin, La Crosse. He was awarded the Dean’s Distinguished Fellowship for a project investigating gonad development in Caenorhabditis Elegans, using in vivo RNA interference. 

He then went on to join Bert O’Malley’s Molecular and Cellular Biology program at Baylor College of Medicine, where he earned his PhD with Franco DeMayo. His graduate work focused on the intersection of progesterone and growth factor signalling, and their role in endometrial receptivity.
While finishing his work there, he was recruited by Mark Hughes of Genesis Genetics to open a Research and Development PGS laboratory in Houston, Texas. Mike quickly rose to prominence as a technical expert and was instrumental in the adoption and implementation of Next Generation Sequencing in Genesis Genetics labs across the world. Shortly after being acquired by CooperSurgical, he was promoted to Director of Genomic Laboratories, overseeing PGT-A testing for approximately 1,000 patients per month for two years. He was then promoted to his current role, leading research efforts in Genomics. His team recently lead and continues to develop state-of-the-art analytical methods for interrogating Reproductive Genetics.